Long-term clinical outcomes of losartan in patients with Marfan syndrome: follow-up of the multicentre randomized controlled COMPARE trial
Study (n=153) suggest a clinical benefit of losartan added to β-blocker treatment in patients with Marfan syndrome, with a reduced number of events compared to the control group (only statistically significant difference for death: 0 vs. 5 and aortic dissection: 3 vs. 11).
Source:
European Heart Journal
SPS commentary:
According to an editorial, in reality, aortic dilatation is used as a surrogate for events of the ascending aorta (surgery or dissection), however, with modern care, the risk for dissection of the ascending aorta is low, close to the risk of dissection of the descending aorta, therefore, it is difficult to gather a large enough population with such a rare disease and, even when combining the results of the published randomised studies, convincing evidence for a benefit of losartan on clinical endpoints is not found. It discusses why the current study findings are in contrast to the other reports. It hopes that a forthcoming meta-analysis combining all of the randomised studies already published or unpublished will confirm the preliminary results of this study.